Searchable abstracts of presentations at key conferences in endocrinology

ea0090s15.1 | Advances in reproductive endocrinology | ECE2023

Effects of kisspeptin in patients with low sexual desire?

Dhillo Waljit S

Successful reproduction in humans at a population level, is reliant on the careful co-ordination of reproductive hormones with associated behaviours. Kisspeptin is a neuropeptide that is critical for normal hypothalamic function of the reproductive hormonal axis. However beyond its hormonal effects, non-human data suggests an emerging role for kisspeptin in a range of animal behaviours through extra-hypothalamic downstream neuroendocrine pathways. Until recently, the roles of ...

ea0019s45 | Kisspeptin: a novel regulator of puberty and fertility | SFEBES2009

What does kisspeptin do in humans?

Dhillo W S

Kisspeptin, the endogenous ligand of the GPR54 receptor, is a key regulator of reproduction. Inactivating mutations of the GPR54 receptor in mice and humans is associated with a failure of reproductive function. Activating mutations in the GPR54 receptor result in precocious puberty. The endogenous neuropeptide agonist for GPR54, kisspeptin, potently stimulates release of gonadotrophins in rodents and primates.Objective: We determined the effects of elev...

ea0007p112 | Endocrine tumours and neoplasia | BES2004

Metastatic glucagonoma de-differentiated to an insulinoma: response to embolization

Dhillo W , Meeran K , Todd J

A 65 year old lady presented to her GP in 1997 with an extensive rash. She was referred to a dermatologist but the rash which failed to settle with topical treatments. A plasma glucagon level was elevated at 275 pmol/l (NR 0-50). CTscan revealed a mass in the pancreatic tail and hepatic metastases consistent with malignant glucagonoma. She was commenced on octreotide and the rash resolved. She underwent a distal pancreatectomy, partial left hepatic lobectomy and intraoperative...

ea0021p117 | Clinical practice/governance and case reports | SFEBES2009

The use of the urine calcium/creatinine clearance ratio in patients with hypercalcaemia

Mahmud Mohammad , Jayasena Channa , Palazzo Fausto , Meeran Karim , Dhillo Waljit

Background: Hypercalcaemia is defined as an elevated serum calcium level above 2.6 mmol/l and occurs in 1 in 1000 of the population. It commonly results from primary hyperparathyroidism (PHP) which is usually treated with parathyroidectomy. A less common cause of hypercalcaemia is familial hypocalciuric hypercalcaemia (FHH) which is caused by mutations inactivating the calcium-sensing receptor; however FHH is relatively benign and requires no treatment. It is clearly important...

ea0013p236 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

PYY3–36 produces an acute anorexigenic effect followed by a later orexigenic effect not seen with other anorexigenic peptides

Parkinson James , Dhillo Waljit , Small Caroline , Ghatei Mohammed , Bloom Stephen

PYY is secreted postprandially from the endocrine L-cells of the gastrointestinal tract. PYY3–36, the major circulating form of PYY, reduces food intake in humans and rodents via high affinity binding to the auto-inhibitory NPY receptor, Y2R, within the hypothalamic arcuate nucleus.Aims: To investigate (1) the effects of length of fast on the anorexigenic actions of PYY3–36; (2) the effects of early light phase administrat...

ea0013p243 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

Use of the dexamethasone-suppressed corticotrophin-releasing hormone test to predict cure in patients with cushing’s disease following pituitary surgery

Banerjee Anita , Martin Niamh , Dhillo Waljit , Roncaroli Federico , Meeran Karim

Establishing failure of trans-sphenoidal surgery (TSS) to cure Cushing’s disease in the immediate post-operative period is essential for early surgical re-exploration. However, there is no consensus regarding the definition of apparent cure. We studied whether the dexamethasone-suppressed corticotrophin-releasing hormone test (LDDST-CRH test) immediately following TSS could accurately identify those with Cushing’s disease requiring further definitive treatment.<p...

ea0012p80 | Pituitary | SFE2006

Long term follow-up of patients treated with Yttrium-90 implants for pituitary adenomas

Manam Seshi , Meeran Karim , Dhillo Waljit , Todd Jeannie

IntroductionYttrium-90 pituitary implants were used in the past as one of the first line treatments for pituitary tumours in many endocrine centres. The procedure involved inserting radioactive rods of Yttrium oxide in to the pituitary fossa. This treatment has been replaced by medical treatment for prolactinomas and transsphenoidal surgery for all other pituitary tumours.AimTo investigate long-term efficacy ...

ea0012p81 | Pituitary | SFE2006

Long term follow-up of patients with a non-functioning pituitary adenoma

Uruthirakumaran Kowchika , Meeran Karim , Todd Jeannie , Dhillo Waljit

Non-functioning pituitary adenomas (NFAs) constitute 25-30% of all pituitary tumours. NFAs do not secrete hormones and patients present with clinical features due to mass effects of the tumour such as visual field defects or hypopituitarism. Surgery and radiotherapy (RT) have been considered standard therapy for patients with a non-functioning macroadenoma. However, since MRI scanning has become widely available fewer patients are routinely referred for RT following surgery.</...

ea0012p130 | Thyroid | SFE2006

Use of a telephone clinic to follow up patients treated with radioactive iodine for thyrotoxicosis

Skennerton S , Nijher GMK , Dhillo WS , Meeran K

IntroductionPatients treated with radioiodine (RAI) for thyrotoxicosis, secondary to Graves or a toxic nodule, require close follow up to determine whether they have become hypothyroid or have a recurrence. National guidelines state that patients should have their first blood test at about six weeks post RAI. Telephoning patients with their results, rather than reviewing them at outpatient appointments, can be a more convenient and efficient method of fo...

ea0011p504 | Endocrine tumours and neoplasia | ECE2006

Headaches cured by surgery

Banerjee A , Balaratnam M , Dhillo W , Mendoza N , Meeran K

Headaches associated with acromegaly are common even after hypophysectomy. Medical treatment with dopamine agonists and Somatostatin analogues often help. We report two cases when pharmacological therapy failed but further surgical removal of residual pituitary tissue cured the headaches.A 38 year-old lady presented with an eight year history of headaches, unresponsive to simple analgesia. Acromegaly was confirmed by a raised serum growth hormone (GH) 33...